MUPIROCIN

Posology Adults (including elderly), adolescents, children and infants aged 4 weeks and older MUPIROCIN ointment should be applied to the affected area two to three times a day for up to 10 days. The area may be covered with a dressing or occluded if desired.

Paediatric population Newborns MUPIROCIN ointment has not been studied in term and preterm newborn infants under 4 weeks of age and therefore it should not be used in these patients until further data become available. 4). Hepatic impairment No dosage adjustment is necessary.

Method of administration Topical. Any product remaining at the end of treatment should be discarded. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction of the antibacterial activity and potential loss of stability of the mupirocin in the ointment.

Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10) common (≥ 1/100 to <1/10) uncommon (≥ 1/1,000 to <1/100) rare (≥ 1/10,000 to <1/1,000) very rare (<1/10,000). Common and uncommon adverse reactions were determined from pooled safety data from clinical studies.

Very rare adverse reactions were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than true frequency.

Immune system disorders Very rare:

Systemic allergic reactions including anaphylaxis, generalised rash, urticaria and angioedema have been reported with mupirocin.

Skin and subcutaneous tissue disorders Common:

Burning localised to the area of application.

Uncommon:

Itching, erythema, stinging and dryness localised to the area of application. Cutaneous sensitisation reactions to mupirocin or the ointment base. Paediatric population Frequency, type and severity of adverse reactions in children are the same as in adults.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Should a possible sensitisation reaction or severe local irritation occur with the use of MUPIROCIN ointment, treatment should be discontinued, the product should be washed off and appropriate therapy instituted. As with other antibacterial products, prolonged use may result in overgrowth of non- susceptible organisms.

Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use.

Although this is less likely to occur with topically applied mupirocin, if prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.

Renal impairment Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol based ointments, MUPIROCIN ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.

MUPIROCIN ointment is not suitable for: • ophthalmic use • intranasal use • use in conjunction with cannulae • at the site of central venous cannulation. Avoid contact with the eyes. If contaminated, the eyes should be thoroughly irrigated with water until the ointment residues have been removed.

Butylated hydroxytoluene may cause local skin reactions (e. g. contact dermatitis), or irritation to the eyes and mucous membranes.

1. This formulation is not suitable for ophthalmic or intranasal use.